The management of Type 2 diabetes involves navigating various risk factors and medications to prevent cardiovascular complications and premature death, with hyperglycemia and oxidative stress playing pivotal roles in diabetic cardiac damage. This study aimed to evaluate the impact of a combination therapy comprising Cholecalciferol and Taurine on Streptozotocin-induced diabetic cardiac damage in male Sprague Dawley rats treated with Metformin. Rats were categorized into six groups, and after inducing diabetes with a high-fat diet and streptozotocin, treatments were administered orally for 6 weeks. Results indicated that the combination of Cholecalciferol, Taurine, and Metformin exhibited superior myocardial protection in diabetic rats compared to those receiving metformin alone. This conclusion was drawn based on a set of assessments, including histopathology, CK-MB levels, and complete blood count. The current study suggests that incorporating cholecalciferol and taurine into diabetes treatment regimens, alongside Metformin, may effectively mitigate cellular cardiac damage associated with hyperglycemia.